Unum Therapeutics

Share on: 
Business Area(s): 
Description: 

Develops PLX9486. PLX9486 is a highly selective and potent inhibitor of mutant KIT D816V with a clinical profile that has been tested in over fifty patients to date. In 2021, Unum plans to clinically test the use of PLX948 in patients with Advanced Systemic Mastocytosis (ASM), Indolent Systemic Mastocytosis (ISM), and patients with advanced gastrointestinal stromal tumors (GIST).

Location(s): 
Cambridge MA
United States